ROCKVILLE, Md.--(BUSINESS WIRE)--Feb. 15, 2006--Celera Genomics Group (NYSE:CRA), an Applera Corporation business, today announced that Abbott (NYSE:ABT) has selected two Celera antigen targets for further investigation and potential therapeutic development. These are in addition to the two targets Abbott selected for advancement in April 2005 and the two targets announced earlier this month. Abbott now has a total of six targets under investigation from the strategic collaboration established between Celera Genomics and Abbott to discover, develop and commercialize therapies for the treatment of cancer.
